Sage Therapeutics - JPM 2025 Presentation.pdf

1、J.P.Morgan Healthcare ConferenceJanuary 2025Sage Therapeutics 2025Safe Harbor Statement2 The slides presentedtoday and the accompanying oral presentations contain forward-lookingstatements,which may be identified by the use of words such as“may,”“might,”“will,”“should,”“can,”“expect,”“plan,”“anticip

2、ate,”“believe,”“estimate,”“project,”“intend,”“future,”“opportunity”,“goal”,“mission”,vision,“potential,”“target”,or“continue,”and other simil ar expressions.Forward-looking statements in this presentation include statements regarding:plans,expectations,strategy and goals for commercialization of ZUR

3、ZUVAE as a treatment for women with PPD,including our goal for ZURZUVAE to become first line therapy and standard of care in this indication,plans to scale and accelerate growth of ZURZUVAE in PPD,our plans to increase investment in ZURZUVAE to help accelerate market and topline revenue growth in 20

4、25 and our overall expectations on the impact of such increased investment,including expectations regarding salesforce expansion,future media campaigns,and disease state awareness efforts and related impacts,expectations on reimbursement and access,and plans and goals related to other aspects of com

5、mercialization;our belief in the potential benefit and profile of ZURZUVAE for the treatment of women with PPD;the potential forsuccess of our commercialization of ZURZUVAE for the treatment of womenwith PPD and our belief in the size of the potential market opportunity in PPD and the role of ZURZUV

6、AE in unlocking such potential;our clinical development plans and expectations,including expected timelines for data read-outs and other activities,such as the expected timing of readout of the multiple ascending dose study for SAGE-319;our plans to apply learnings and advance a recalibrated and foc